A circular RNA (circRNA) drug enhanced saliva production in radiation-induced xerostomia, a promising development in the ...
We’ve also begun drug discovery efforts of our own,’ Anthropic says, as it buys Mithril and reports Claude results from six ...
Izalontamab brengitecan nearly doubled PFS compared with chemotherapy ...
Astra Zeneca and CSL have publicly endorsed Clever Culture's APAS agar plate reading tech – or at least they have come close ...
CAR T therapy multiple sclerosis trial death: Bristol Myers Squibb disclosed the first fatality in its Phase 1 Breakfree-2 ...
BioNTech SE and Bristol Myers Squibb Company reported initial results from the global Phase 2 ROSETTA Lung-107 study of ...
VisIC Technologies and AVL integrate GaN traction inverter into vehicle demonstrator, achieving over 99.8% efficiency and ...
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. A published study demonstrated that combining Tempus RNA and DNA testing increases ...
India is emerging as a center of scientific innovation, commercial growth and global capability. For US and European life ...
(NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS ...
Substantially improved specificity of 2025 classification criteria for axial spondyloarthritis relative to 2009 criteria is largely driven by improved MRI methodology that clinicians must understand.